IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | | |
|---|---|---|---|
| Applicant: | Maria Fardis et al. | Examiner: | Unknown |
| Serial No.: | 10/583,573 | Group Art Unit: | Unknown |
| Filed: | June 19, 2006 | Docket: | 01692.258US2 |
| Title: | 4'-SUBSTITUTED CARBOVIR AND ABACAVIR-DERIVATIVES AS WELL AS RELATED COMPOUNDS WITH HIV AND HCV ANTIVIRAL ACTIVITY | | |



## INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with 37 C.F.R. § 1.56, and in accordance with 37 C.F.R. §§ 1.97 *et. seq.*, the enclosed materials are brought to the attention of the Examiner for consideration in connection with the above-identified patent application. Applicant respectfully requests that this Information Disclosure Statement be entered and the documents listed on the attached Form 1449 be considered by the Examiner and made of record. Pursuant to MPEP 609, Applicant requests that a copy of the Form 1449, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication. Applicant also encloses a copy of the corresponding International Search Report for your convenience.

Pursuant to 37 C.F.R. § 1.97, no fee or statement is required with the Information Disclosure Statement. However, the Commissioner is hereby authorized to charge the required fees to Deposit Account No. 503503 in order to have this Information Disclosure Statement considered if required. The Examiner is invited to contact the Applicant's Representative at the below-listed telephone number if there are any questions regarding this communication.

Respectfully submitted,
Maria Fardis et al.
By their Representatives,
Viksnins Harris & Padys PLLP
P.O. Box 111098
St. Paul, MN 55111-1098
952 876-4092

Date 11-1-06 By _____
Robert J. Harris
Reg. No. 37,346

CERTIFICATION OF HAND DELIVERY: The undersigned certifies that this correspondence is being hand delivered to the United States Patent Office in an package addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on this ____ day of November 2006.

_____ _____
Typed or Printed Name of Person Signing Certificate Signature

PTO/SB/21 (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE


# TRANSMITTAL FORM

*(to be used for all correspondence after initial filing)*

Total Number of Pages in This Submission

| | |
|---|---|
| Application Number | 10/583,573 |
| Filing Date | June 19, 2006 |
| First Named Inventor | Maria Fardis |
| Art Unit | Unknown |
| Examiner Name | Unknown |
| Attorney Docket Number | 01692.258US2 |

## ENCLOSURES *(Check all that apply)*

- ☐ Fee Transmittal Form
  - ☐ Fee Attached
- ☐ Amendment/Reply
  - ☐ After Final
  - ☐ Affidavits/declaration(s)
- ☐ Extension of Time Request
- ☐ Express Abandonment Request
- ☑ Information Disclosure Statement
- ☐ Certified Copy of Priority Document(s)
- ☐ Reply to Missing Parts/ Incomplete Application
  - ☐ Reply to Missing Parts under 37 CFR 1.52 or 1.53
- ☐ Drawing(s)
- ☐ Licensing-related Papers
- ☐ Petition
- ☐ Petition to Convert to a Provisional Application
- ☐ Power of Attorney, Revocation Change of Correspondence Address
- ☐ Terminal Disclaimer
- ☐ Request for Refund
- ☐ CD, Number of CD(s) _____
  - ☐ Landscape Table on CD
- ☐ After Allowance Communication to TC
- ☐ Appeal Communication to Board of Appeals and Interferences
- ☐ Appeal Communication to TC **(Appeal Notice, Brief, Reply Brief)**
- ☐ Proprietary Information
- ☐ Status Letter
- ☑ Other Enclosure(s) (please Identify below):

Form 1449 (6 pgs.); Copies of 84 cited references; Return Postcard

Remarks

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

| | | | |
|---|---|---|---|
| Firm Name | VIKSNINS HARRIS & PADYS PLLP | | |
| Signature |  | | |
| Printed name | Robert J. Harris | | |
| Date | November 1, 2006 | Reg. No. | 37,346 |

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

| | | | |
|---|---|---|---|
| Signature | | | |
| Typed or printed name | | Date | |

| Substitute for form 1449A/PTO and/or 1449B/PTO<br>**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**<br>*(Use as many sheets as necessary)* | *Complete if Known* | |
|---|---|---|
| | **Application Number** | 10/583,573 |
| | **Filing Date** | June 19, 2006 |
| | **First Named Inventor** | Maria Fardis |
| | **Group Art Unit** | Unknown |
| | **Examiner Name** | Unknown |
| Sheet 1 of 6 | 01692.258US2 | |

| US PATENT DOCUMENTS | | | |
|---|---|---|---|
| **Examiner Initials *** | **US Document Number** | **Publication Date** | **Name of Patentee/Applicant of Document** |
| | US 5,413,996 | 05-09-1995 | Bodor, Nicholas S. |
| | US 5,670,497 | 09-23-1997 | Bold, Guido *et al.* |
| | US 5,750,493 | 05-12-1998 | Schinazi, Raymond F. *et al.* |
| | US 5,874,577 | 02-23-1999 | Chen, Wei *et al.* |
| | US 5,914,332 | 06-22-1999 | Chen, Xiaoqi *et al.* |
| | US 6,072,053 | 06-06-2000 | Vince, Robert *et al.* |
| | US 6,312,662 | 11-06-2001 | Robinson, Edward D. *et al.* |
| | US 5,750,343 | 05-12-1998 | Maag, Hans *et al.* |
| | US 6,767,900 | 07-27-2004 | Ubasawa, Masaru *et al.* |
| | US 2001-031773 | 10-18-2001 | Camden, James Berger |
| | US-2003-0109498 | 06-12-2003 | Yuasa, Satoshi *et al.* |

| FOREIGN PATENT DOCUMENTS | | | |
|---|---|---|---|
| **Examiner Initials*** | **Foreign Document Number (include country code)** | **Publication Date** | **Translation (Abstract Only or Full Translation, if applicable)** |
| | EP 0 267 050 | 05-11-1988 | |
| | EP 0 441 192 | 01-25-1991 | |
| | EP 0 465 297 | 01-08-1992 | |
| | EP 0 531 597 | 03-17-1993 | |
| | EP 0 632 048 | 01-04-1995 | |
| | EP 0 786 455 | 07-30-1997 | |
| | EP 0 852 233 | 07-08-1998 | |
| | EP 0 919 562 | 06-02-1999 | |
| | EP 1 295 879 | 03-26-2003 | |
| | WO 88/06158 | 08-25-1988 | |
| | WO 91/19721 | 12-26-1991 | |
| | WO 92/00988 | 01-23-1992 | |
| | WO 92/18520 | 10-29-1992 | |
| | WO 93/12123 | 06-24-1993 | |
| | WO 93/24510 | 12-09-1993 | |
| | WO 96/14314 | 05-17-1996 | |
| | WO 96/40156 | 12-19-1996 | |
| | WO 98/04569 | 02-05-1998 | |
| | WO 98/11906 | 03-26-1998 | |
| | WO 99/62921 | 12-09-1999 | |
| | WO 00/04033 | 01-27-2000 | |
| | WO 01/13957 | 03-01-2001 | |

**EXAMINER** **DATE CONSIDERED**

| Substitute for form 1449A/PTO and/or 1449B/PTO<br>**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**<br>*(Use as many sheets as necessary)* | *Complete if Known* | |
|---|---|---|
| | **Application Number** | 10/583,573 |
| | **Filing Date** | June 19, 2006 |
| | **First Named Inventor** | Maria Fardis |
| | **Group Art Unit** | Unknown |
| | **Examiner Name** | Unknown |
| Sheet 2 of 6 | 01692.258US2 | |

| FOREIGN PATENT DOCUMENTS | | | |
|---|---|---|---|
| **Examiner Initials*** | **Foreign Document Number (include country code)** | **Publication Date** | **Translation (Abstract Only or Full Translation, if applicable)** |
| | WO 01/17982 | 03-15-2001 | |
| | WO 01/19320 | 03-22-2001 | |
| | WO 01/46204 | 06-28-2001 | |
| | WO 01/64693 | 09-07-2001 | |
| | WO 01/96329 | 12-20-2001 | |
| | WO 02/03997 | 01-17-2002 | |
| | WO 02/06292 | 01-24-2002 | |
| | WO 02/08241 | 01-31-2002 | |
| | WO 02/14344 | 02-21-2002 | |
| | WO 02/057425 | 07-25-2002 | |
| | WO 02/100415 | 12-19-2002 | |
| | WO 03/028737 | 04-10-2003 | |
| | WO 03/050129 | 06-19-2003 | |
| | WO 03/059255 | 07-24-2003 | |
| | WO 03/064383 | 08-07-2003 | |
| | WO 03/066005 | 08-14-2003 | |
| | WO 03/080078 | 10-02-2003 | |
| | WO 03/090690 | 11-06-2003 | |
| | WO 2004/096234 | 11-11-2004 | |
| | WO 2005/011709 | 02-10-2005 | |

| OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS | |
|---|---|
| **Examiner Initials*** | **Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source (book, magazine, journal, serial, symposium, catalog, *etc.*), Volume-Number, page(s) and (date).** |
| | ABDEL-MEGUID, SHERIN S. *et al.*, Inhibition of Human Immunodeficiency Virus-1 Protease by a $C_2$-Symmetric Phosphinate. Synthesis and Crystallographic Analysis, *Biochemistry*, 1993, 1543-1572, Vol. 32, No. 31. |
| | ALLEN, LEE F. *et al.*, CI-1040 (PDI84352), a Targeted Signal Transduction Inhibitor of MEK (MAPKK), *Seminars in Oncology*, October 2003, pp. 105-116, Vol. 30, No. 5, Elsevier Inc. |
| | BANTIA, SHANTA *et al.*, Purine nucleoside phosphorylase inhibitor BCX-1777 (Immucillin-H)—a novel potent and orally active immunosuppressive agent, *International Immunopharmacology*, 2001, pp. 1199-1210, Elsevier Science B.V. |
| | BEAUCHAMP, LILIA M., *et al.*, Guanine, Pyrazolo[3,4-d]pyrimidine, and Triazolo[4,5-d]pyrimidine(8-Azaguanine) Phosphonate Acyclic Derivatives as Inhibitors of Purine Nucleoside Phosphorylase, *Journal of Medicinal Chemistry*, 1996, pp. 949-956, American Chemical Society. |
| | BOHANI D. W. *et al.*, A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection, *Bioorganic & Medicinal Chemistry Letters,* 2004, Vol. 14. |

**EXAMINER** **DATE CONSIDERED**

| Substitute for form 1449A/PTO and/or 1449B/PTO<br>**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**<br>*(Use as many sheets as necessary)* | *Complete if Known* | |
|---|---|---|
| | **Application Number** | 10/583,573 |
| | **Filing Date** | June 19, 2006 |
| | **First Named Inventor** | Maria Fardis |
| | **Group Art Unit** | Unknown |
| | **Examiner Name** | Unknown |
| Sheet 3 of 6 | 01692.258US2 | |

| OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS | |
|---|---|
| **Examiner Initials*** | **Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source (book, magazine, journal, serial, symposium, catalog, *etc.*), Volume-Number, page(s) and (date).** |
| | BZOWSKA, AGNIESZKA *et al.*, Purine nucleoside phosphorylases: properties, functions, and clinical aspects, *Pharmacology & Therapeutics*, 2000, pp. 349-425, Vol. 88, Elsevier Science Inc. |
| | CHAPMAN, H. *et al.*, Practical Synthesis, Separation, and Stereochemical Assignment of the PMPA Pro-Drug GS-7340, Nucleosides, Nucleotides & Nucleic Acids, 2001, pp. 621-628, Vol. 20, Nos. 4-7, Marcel Dekker, Inc. |
| | CLARK, JEREMY L. *et al.*,<br>Mycophenolic Acid Analogues as Potential Agents Against West Nile Virus Infection. |
| | CONKLYN, MARYROSE *et al.*, The JAK3 inhibitor CP-690550 selectively reduces NK and CD8+ cell numbers in cynomolgus monkey blood following chronic oral dosing, *Journal of Leukocyte Biology*, December 2004, pp. 1-8, Vol. 76, The Society for Leukocyte Biology. |
| | DE CLEREQ, E., Highlights in the Development of New Antiviral Agents, *Mini Reviews in Medicinal Chemistry*, 2002, 163-175, Vol. 2, No. 2., Bentham Science Publishers, Ltd. |
| | DE CLERCQ, ERIK, New Developments in Anti-HIV Chemotherapy, *Current Medicinal Chemistry*, 2001, 1543-1572, Vol. 8, No. 13, Bentham Science Publishers Ltd. |
| | DVORAKOVA, HANA *et al.*, Synthesis of 2'-Aminomethyl Derivatives of N-(2-(Phosphonomethoxy)ethyl) Nucleotide Analogues as Potential Antiviral Agents, *J. Med. Chem.*, 1996, 3263-3268. Vol. 38, No. 17. |
| | EVANS, GARY B., Exploring Structure -- Activity Relationships of Transition State Analogues of Human Purine Nucleoside Phosphorylase, *J. Med. Chem.*, 2003, 3412-3423, Vol. 46, No. 15, American Chemical Society. |
| | GUMINA, GIUSEPPE *et al.*, Advances in antiviral agents for hepatitis B virus, *Antiviral Chemistry & Chemotherapy*, 2001, 93-112, Vol. 12, Suppl. 1, International Medical Press. |
| | GOBEC, S. *et al.*, Phosphonate inhibitors of antiget 85C, a crucial enzyme involved in the biosynthesis of the mycobacterium tuberculosis cell wall, *Bioorganic and Medicinal Chemistry Letters*, 2004, Vol. 14. |
| | HEGEDUS, LOUIS S. *et al.*, Synthesis of 4'-Methyl and 4'-cyano Carbocyclic 2',3'-Didehydro Nucleoside Analogues via 1,4-Addition to Substituted Cyclopentenones, *J. Org. Chem.*, 2004, 8492-8495, Vol. 69, No. 24, American Chemical Society. |
| | HERCZEGH P., *et al.*, Osteoadsorptive bisphosphonate derivatives of fluoroquinolone antibacterials, *J. Med. Chem.*, 2002, Vol. 45. |
| | HIRABAYASHI, HIDEKI *et al.*, Bone-Specific Drug Delivery Systems, *Clinical Pharacokinetics*, 2003, 1319-1330, Vol. 42, No. 15. |
| | HOLY A. *et al.*, Synthesis, *Cllect. Czech. Chem. Commun.*, 1989, Vol. 54, pages 2190-2210. |
| | JAIN, JUGNU *et al.*, Characterization of Pharmacological Efficacy of VX-148, a New, Potent Immunosuppressive Inosine 5'-Monophosphate Dehydrogenase Inhibitor, *Journal of Pharmacology and Experimental Therapeutics*, 2002, 1272-1277, Vol. 302, No. 3, The American Society for Pharmacology and Experimental Therapeutics. |
| | KARPENKO, INNA L. *et al.*, Synthesis and Antitherpetic Activity of Acyclovir Phosphonates, *NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS*, 2003, 319-328, Vol 22, No. 3, Marcel Dekker, Inc. |

**EXAMINER** **DATE CONSIDERED**

| Substitute for form 1449A/PTO and/or 1449B/PTO<br>**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**<br>*(Use as many sheets as necessary)* | *Complete if Known* | |
|---|---|---|
| | **Application Number** | 10/583,573 |
| | **Filing Date** | June 19, 2006 |
| | **First Named Inventor** | Maria Fardis |
| | **Group Art Unit** | Unknown |
| | **Examiner Name** | Unknown |
| Sheet 4 of 6 | 01692.258US2 | |

| OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS | |
|---|---|
| **Examiner Initials*** | **Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source (book, magazine, journal, serial, symposium, catalog, *etc.*), Volume-Number, page(s) and (date).** |
| | KATO, KEISUKE *et al.*, Stereoselective synthesis of 4' -.alpha.-alkyclcarbovir derivatives based on an asymmetric synthesis or chemo-enzymatic procedure, *Chemical & Pharmaceutical Bulletin*, 1999, 1256-1264, Vol. 49, No. 9, Pharmaceutical Society of Japan. |
| | KATO, KEISUKE *et al.*, Enantio- and diastereoselective syntheis of 4'-α-substituted carbocyclic nucleosides, Tetrahedron: *Asymmetry*, 1998, 911-914, Vol. 9, Elsevier Science Ltd. |
| | KILPATRICK, J. MICHAEL, Intravenous and oral pharmacokinetic study of BCX-1777, a novel purine nucleoside phosphorylase transition-state inhibitor, In vivo effects on blood 2'-deoxyguanosine in primates, *International Immunopharmacology*, 2003, 541-548, Vol. 3, Elsevier Science B.V. |
| | KIM, CHOUNG UN *et al.*, Regiospecific and Highly Stereoselective Electrophilic Addition to Furanoid Glycals: Synthesis of Phosphonate Nucleotide Analogues with Potent Activity against HIV, J. Org. Chem., 1991, 2642-2647, Vol. 56, No. 8, American Chemical Society. |
| | KINSKY, STEPHEN C. *et al.*, Inhibition of cell proliferation by putative metabolites and non-degradable analogs of methotrexate-.gama.-dimyristoylphosphatidylethanolamine, *Biochimica et Biphysica Acta,* 19878, 211-218, Vol. 917, No. 2., Elsevier Science Publishers B. V. |
| | KINSKY, STEPHEN C. *et al.*, Effect of liposomes sentitized with methotrexate-γ-dimyristoylphosphatidylethanolamine on cells that are resistant to methotrexate, *Biochimica et Biophysica Acta*, 1986, 129-135, Vol. 885, Elsevier Science Publishers B.V. |
| | KINSKY, STEPHEN C. *et al.*, Circumvention of the methotrexate transport system by methotrexate-phosphatidylethanolamine derivatives effect of fatty acid chain length, *Biochimica et Biophysica Acta*, 1987, 96-103, Vol. 921, Elsevier Science Publishers B.V. |
| | KO, OK HYUN *et al.*, Efficient synthesis of novel carbocyclic nucleosides via sequential Claisen rearrangement and ring-closing metathesis, *Tetrahedron Letters*, 2002, 6399-6402, Vol. 43, Elsevier Science Ltd. |
| | LEWANDOWICZ, ANDRZEJ *et al.*, Achieving the Ultimate Physiological Goal in Transition State Analogue Inhibitors for Purine Nucleoside Phosphorylase, *The Journal of Biological Chemistry*, 2003, 31465-31468, Vol. 278, No. 34, The American Society for Biochemistry and Molecular Biology, Inc. |
| | MENENDEZ-ARIAS, LUIS *et al.* Targeting HIV: antiretroviral therapy and development of drug resistance, *TRENDS in Pharmacological Sciences*, 2002, 381-388, Vol. 23, No. 8, Elsevier Science Ltd. |
| | ONO-NITA, SUZANE KIOKO *et al.*, Novel Nucleoside Analogue MCC-478 (LY582563) Is Effective against Wild-Type or Lamivudine-Resistant Hepatitis B Virus, *Antimicrobial Agents and Chemotherapy*, 2002, 2602-2605, Vol. 46, No. 8, American Society for Microbiology. |
| | PANKIEWICZ, KRZYSZTOF W., Novel Mycophenolic Adenine Bis(phosphonate) Analogues As Potential Differentiation Agents against Human Leukemia, *J. Med. Chem.*, 2002 703-712, Vol. 45, No. 3, American Chemical Society. |
| | PARANG, KEYKAVOUS *et al.*, Novel Approaches for Designing 5'-O-Ester Prodrugs of 3'-Azido-2', 3'-dideoxythymidine (AZT), *Current Medicinal Chemistry*, 2000, 995-1039, Vol. 7, No. 10, Bentham Science Publishers Ltd. |
| | PRASHAD, MAHAVIR *et al.*, An Efficient and Large-Scale Enantioselective Synthesis of PNP405: A Purine Nucleoside Phosphorylase Inhibitor, *J. Org. Chem.*, 2002, 6612-6617, Vol. 67, No. 19, American Chemical Society. |

**EXAMINER** **DATE CONSIDERED**

| Substitute for form 1449A/PTO and/or 1449B/PTO<br>**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**<br>*(Use as many sheets as necessary)* | *Complete if Known* | |
|---|---|---|
| | **Application Number** | 10/583,573 |
| | **Filing Date** | June 19, 2006 |
| | **First Named Inventor** | Maria Fardis |
| | **Group Art Unit** | Unknown |
| | **Examiner Name** | Unknown |
| Sheet 5 of 6 | 01692.258US2 | |

| OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS | |
|---|---|
| **Examiner Initials*** | **Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source (book, magazine, journal, serial, symposium, catalog, *etc.*), Volume-Number, page(s) and (date).** |
| | RAY, ADRIAN S. *et al.*, Role of Purine Nucleoside Phosphorylase in Interactions between 2', 3'-Dideoxyinosine and Allopurinal, Ganciclovir, or Tenofovir, Antimicrobial Agents and Chemotherapy, 2004, 1089-1095, Vol. 48, No. 4, American Society for Microbiology. |
| | REED, LEFF *et al.*, Antidiabetic PPARγ Ligands: An update on Compounds in development, *Curr. Med. Chem. – Imun., Endoc. & Metab. Agents*, 2002, 33-47, Vol. 2, No. 1, Bentham Science Publishers Ltd. |
| | ROBERTS, STANLEY M., Development of the route to the new anti-AIDS drug abacavir: A highlight of academic/industry laison, *IDrugs*, 1998, 896-899, Vol. 1, No. 8, Current Drugs Ltd. |
| | ROSOWSKY, ANDRE *et al.*, METHOTREXATE ANALOGUES—27, *Biochemical Pharmacology*, 1986, 3327-3333, Vol. 35, No. 19, Pergamon Journals Ltd. |
| | ROSOWSKY, ANDRE *et al.*, Methotrexate Analogues, 32, Chain Extension, α-Carboxyl Replacement by Sulfonate and Phosphonate: Effect on Enzyme Binding and Cell-Growth Inhibition, *J. Med. Chem.*, 1988, 1326-1331, Vol. 31, No. 7, American Chemical Society. |
| | SCHULTZ, C., Prodrugs of biologically active phosphate esters, *Bioorganic & Medicinal Chemistry*, 2003, 885-898, Vol. 11, Elsevier Science Ltd., GB. |
| | SEKIYA, KOUICHI *et al.*, 2-Amino-6-arylthio-9-[2-(phosphonomethoxy) ethyl) purine Bis(2,2,2-trifluoroethyl) Esters as Novel HBV-Specific Antiviral Reagents, Journal of Medicinal Chemistry, 2002, 3138-3142, Vol. 45, No. 14, American Chemical Society. |
| | SHI, WUXIAN *et al.*, *Plasmodium falciparum* Purine Nucleoside Phosphorylase, The Journal of Biological Chemistry, 2004, 18103-18106, Vol. 279, No. 18, The American Society of Biochemistry and Molecular Biology, Inc. |
| | SINTCHAK, MICHAEL D. *et al.*, The structure of inosine 5'-monophosphate dehydrogenase and the design of novel inhibitors, Immunopharmachology, 2000, 163-184, Vol. 47, Elsevier. |
| | SRINIVAS, RANGA V. *et al.*, Metabolism and In Vitro Antiretroviral Activities of Bis(Pivaloyloxymethyl) Prodrugs of Acyclic Nucleoside Phosphonates, Antimicrobial Agents and Chemotherapy, 1993, 2247-2250, Vol. 37, No. 10, American Society for Microbiology. |
| | STURTZ, GEORGES *et al.*, Su rune nouvelle approche de pharmacomodulation du methotrexate: synthese d'analogues gem-diphosphoniques d'amethopterine et de la N-10 deaza amethopterine, Medicinal Chemistry, C. R. Acad. Sci. Paris, 1990, Vol. 10, No. 2, 739-742, Academie des Sciences. |
| | STURTZ, GEORGES *et al.*, Analogues phosphonoglutamiques d'amethopterine (methotrexate), Eur. J. Med. Chem – Chim. Ther., 1984, 267-273, Vol. 19, No. 3. |
| | STURTZ, G. *et al.*, Synthesis of gem-bisphosphonic methotrexate conjugates and their biological response towards Walker's osteosarcoma, *Eur. J. Med. Chem.*, 1993, 899-903, Vol. 28, Elsevier. |
| | STURTZ, G. *et al.*, A study of the delivery-targeting concept applied to antineoplasic drugs active on human osteosarcoma, I. Synthesis and biological activity in nude mice carrying human osteosarcoma xenografts of gem-bisphosphonic methotrexate analogues, Eur J. Med. Chem., 1992, 825-833, Vol. 27, No. 8, Elsevier. |
| | VIELHABER, BERND, Bericht vom 3rd International Workshop on Salvage Therapy for HIV-Infection, *Deutsche Aids-Hilfe e.V. FaxReport zu HIV und AIDS,* 2000, 12-14. |
| | WAEGELL W. *et al.* A420983, a novel, small molecule inhibitor of LCK prevents allograft rejection, Transplantation Proceedings, 2002, 1411-1417, Vol. 34. |

**EXAMINER** **DATE CONSIDERED**

| Substitute for form 1449A/PTO and/or 1449B/PTO<br>**INFORMATION DISCLOSURE STATEMENT BY APPLICANT**<br>*(Use as many sheets as necessary)* | *Complete if Known* | |
|---|---|---|
| | **Application Number** | 10/583,573 |
| | **Filing Date** | June 19, 2006 |
| | **First Named Inventor** | Maria Fardis |
| | **Group Art Unit** | Unknown |
| | **Examiner Name** | Unknown |
| Sheet 6 of 6 | 01692.258US2 | |

| OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS | |
|---|---|
| **Examiner Initials*** | **Include last name of the first author (in CAPITAL letters), "Title of the Article", Title of the Source (book, magazine, journal, serial, symposium, catalog, *etc.*), Volume-Number, page(s) and (date).** |
| | WROBLEWSKI, ANDRZEJ *et al.*, Synthesis of (1R,2S)- and (1S,2S)-3-(4-carbamoyl-1,2,3-triazol-1-yl)-1,2-dihydroxypropylphosphonates, Tetrahedron: Asymmetry, 2004, 1457-1464, Vol. 15, Elsevier. |

**EXAMINER** **DATE CONSIDERED**